Perjeta ® 

Substance active: pertuzumab

Domaine thérapeutique: Oncologie

Perjeta est un anticorps monoclonal recombinant, utilisé dans le traitement de certaines formes de cancer du sein.

Notice scientifique Perjeta (pertuzumab)

En savoir plus sur Perjeta?

If a pregnancy occurs while using Perjeta or within 6 months following the last dose of Perjeta, please immediately report pregnancy to the local Roche Adverse Event Line at +32 2 525 82 99. Additional information will be requested during a Perjeta-exposed pregnancy and the first year of the infant’s life. This will enable Roche to better understand the safety of Perjeta and to provide appropriate information to health authorities, healthcare providers and patients.